Caliway CBL-514 Phase 2 Dercum's Success
Analysis based on 6 articles · First reported Sep 23, 2026 · Last updated Sep 23, 2026
The positive Phase 2 results strengthen the clinical and commercial outlook for Caliway Biopharmaceuticals, potentially supporting future licensing deals and expanding the addressable market into Lipedema, though the stock traded slightly lower as the data may have been largely anticipated. Broader market impact is limited given the company's small capitalization and the niche rare-disease indication, but the readout reinforces investor interest in adipose-targeting therapeutics.
Caliway Biopharmaceuticals announced on September 21, 2026, final statistical results from its randomized, single-blind, placebo-controlled Phase 2 clinical trial CBL-0202DD evaluating CBL-514 for the treatment of Dercum's Disease, a rare disorder characterized by painful lipomas. The trial successfully achieved its primary efficacy endpoint, with CBL-514 demonstrating clinically meaningful and statistically significant pain reduction in both the Full Analysis Set and Per-Protocol populations. At Week 20, CBL-514 treated patients achieved a mean pain-score reduction of 3.1 points versus 1.9 points for placebo in the FAS population (p=0.005), and 3.1 versus 1.4 points in the PP population (p=0.0002). Secondary endpoints at Weeks 16 and 24 also reached statistical significance, with reductions of 3.5 and 4.1 points respectively, and the magnitude of response increased over time, supporting durability. Approximately 90 percent of treated patients achieved a clinically meaningful pain reduction of at least 3 points in more than half of their treated painful lipomas. CBL-514 was generally well tolerated, with no drug-related serious adverse events reported. There are currently no approved therapies specifically indicated for Dercum's Disease, and the global market is projected to reach approximately US$19.96 billion by 2030. The company also highlighted expansion potential for CBL-514 in Lipedema, a condition affecting roughly 10 percent of women worldwide with a market opportunity exceeding US$30 billion, and plans to collaborate with clinical experts to evaluate further development. Caliway Biopharmaceuticals is listed on the Taiwan Stock Exchange under ticker 6919, and its shares traded down about 1.82 percent at TW$81.10 following the announcement.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard